Covid-19
Estudo sugere que os sintomas da Covid longa afetem 1 em cada 8 pacientes.
22 Ago, 2022 | 14:59hComunicado de imprensa: Most reliable estimates to date suggest one in eight COVID-19 patients develop long COVID symptoms – Lancet
Comentários:
Long COVID symptoms affect 1 in 8 adults, some for 2 years – CIDRAP
Covid-19: One in eight adults develops long covid symptoms, study suggests – The BMJ
Reino Unido aprova uso da vacina atualizada da Moderna para a variante Ômicron.
22 Ago, 2022 | 14:55hUK approves updated Moderna vaccine targeting Omicron variant – Associated Press/MedicalXpress
Ver também: Covid: UK first country to approve dual-strain vaccine – BBC
Vivendo com as consequências psicológicas da pandemia de COVID-19: revisão sistemática de intervenções efetivas de mitigação.
22 Ago, 2022 | 14:50h
M-A | Eficácia e segurança da anticoagulação com heparina em dose plena em pacientes de COVID-19 internados e não críticos.
16 Ago, 2022 | 13:04hConteúdos relacionados:
Anticoagulants for people hospitalised with COVID‐19 – Cochrane Library
Revisão | Cefaleia da COVID longa.
16 Ago, 2022 | 13:03hLong COVID headache – The Journal of Headache and Pain
Comentário no Twitter
#Headache is among the most frequent symptoms persisting or newly developing after #coronavirus disease 2019 (COVID-19) as part of the so-called long #COVID syndrome. Learn more: https://t.co/v1V2jZBluq pic.twitter.com/X6eAgaOaBF
— European Headache Federation (@EHF_Official) August 4, 2022
Sob licença de http://creativecommons.org/licenses/by/4.0/
Revisão | Complicações cardiovasculares de infecções por COVID-19 associadas a gravidez.
15 Ago, 2022 | 13:40hComentários:
Cardiovascular Complications of COVID-19 in Pregnancy Reviewed – HealthDay
Revisão | A pandemia de COVID-19 e suas consequências para dor crônica.
15 Ago, 2022 | 13:36hThe COVID-19 pandemic and its consequences for chronic pain: a narrative review – Anaesthesia
Comentário no Twitter
🔐Time to pay attention to the consequences of persistent pain in patients after any severity of COVID-19, with increased risk of post-intensive care syndrome in patients requiring ICU care?@harshamd5 @ANels_MD @NarouzeMD #FreeForAWeek
🔗https://t.co/NaafjxCbXz pic.twitter.com/Zj2OGIPniP
— 𝘈𝘯𝘢𝘦𝘴𝘵𝘩𝘦𝘴𝘪𝘢 (@Anaes_Journal) August 1, 2022
Estudo RECOVERY | Baricitinibe em pacientes hospitalizados com COVID-19.
5 Ago, 2022 | 16:50hComentário convidado: Baricitinib in COVID-19: a coming-of-age from artificial intelligence to reducing mortality – The Lancet
Conteúdos relacionados:
WHO recommends two new drugs to treat COVID-19 – World Health Organization
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19 – New England Journal of Medicine
Comentário no Twitter
New @TheLancet
The largest trial of baricitinib, a JAK-inhibitor drug repurposed via #AI data mining, reduced Covid mortality and the overall reduction consistent with 8 previous RCTs (~20%)https://t.co/5fHDBBvm3Q pic.twitter.com/GDFzcU26H6— Eric Topol (@EricTopol) July 29, 2022
Sob licença de Creative Commons Attribution (CC BY 4.0)
Revisão sistemática | Testes rápidos de antígeno para diagnóstico de infecção por SARS-CoV-2.
1 Ago, 2022 | 15:23hRapid, point‐of‐care antigen tests for diagnosis of SARS‐CoV‐2 infection – Cochrane Library
Resumo: How accurate are rapid antigen tests for diagnosing COVID-19? – Cochrane Library
Estudo randomizado | Tixagevimabe-cilgavimabe para tratamento de pacientes internados com COVID-19.
18 Jul, 2022 | 13:36hComentário: The potential of tixagevimab–cilgavimab for treating hospitalized COVID-19 patients – News Medical
Conteúdos relacionados:
Comentário no Twitter
In pts hospitalised w/ COVID-19 receiving remdesivir and other standard care, tixagevimab–cilgavimab did not improve time to sustained recovery but was safe and mortality was lower vs placebo
From the ACTIV-3–TICO Study Group https://t.co/zaaXBQYl5t pic.twitter.com/xe0tmbFrZ9
— The Lancet Respiratory Medicine (@LancetRespirMed) July 11, 2022